行情

CPRX

CPRX

触媒制药公司
NASDAQ

实时行情|Nasdaq Last Sale

3.980
-0.220
-5.24%
盘后: 3.920 -0.06 -1.51% 19:57 01/24 EST
开盘
4.200
昨收
4.200
最高
4.210
最低
3.980
成交量
192.22万
成交额
--
52周最高
7.67
52周最低
2.170
市值
4.10亿
市盈率(TTM)
47.72
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CPRX 新闻

  • Can Catalyst Pharmaceuticals Stock Rebound in 2020?
  • MotleyFool.com.3天前
  • Implied Volatility Surging for Catalyst (CPRX) Stock Options
  • Zacks.01/15 13:58
  • Catalyst Pharmaceuticals Option Alert: Jun 19 $2.5 Calls Sweep (24) near the Ask: 721 @ $2.101 vs 2259 OI; Ref=$4.19
  • Benzinga.01/14 15:11
  • Catalyst Gives Preliminary Firdapse Estimates & Other Updates
  • Zacks.01/07 14:17

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

CPRX 简况

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
展开

Webull提供Catalyst Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。